结直肠癌中IZUMO2的表达与临床病理特征相关
Toshiya Higashi1, Hirokatsu Hayashi1, Yuki Hanamatsu2
1Department of Gastroenterological Surgery and Pediatric Surgery, Gifu University Graduate School of Medicine, Gifu, Japan.
Pathology, research and practice
|March 14, 2024
概括
在结直肠癌的入侵前线,IZUMO2蛋白表达表明预后较差. 这一发现表明IZUMO2可能成为结直肠癌患者的新预后生物标志物.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- IZUMO2是一种丸表达的蛋白质,具有IZUMO域.
- IZUMO2是一种甲基化驱动的基因,与结直肠癌 (CRC) 的预后有关.
- 在CRC中IZUMO2蛋白的表达状态尚不清楚.
研究的目的:
- 为了研究IZUMO2蛋白在结直肠癌组织中的表达.
- 为了将IZUMO2表达与临床病理特征和患者存活率相关联.
- 为了确定IZUMO2在结直肠癌的预后意义.
主要方法:
- 免疫组织化学被用来检测IZUMO2表达在64个结直肠癌样本.
- 进行了卡普兰-梅尔分析,以评估整体存活率 (OS) 和无进展生存率 (PFS).
- 考克斯的比例危险回归模型被用来确定独立的预后因素.
主要成果:
- 在64个 (46.9%) 的结直肠癌样本中,在30个样本中观察到IZUMO2的免疫活性,主要是在入侵前线.
- 患有IZUMO2免疫不活性的患者显示显著更短的OS和PFS (P = 0.046和P = 0.019,分别).
- IZUMO2免疫活性是CRC中PFS差,结肠癌中OS和PFS差的独立预测因子.
结论:
- IZUMO2在显著的结直肠癌子集中表达,特别是在入侵前线.
- IZUMO2的表达与不良的临床结果有关,这表明它作为一个不良预后生物标志物的潜力.
- 进一步研究IZUMO2在结直肠癌进展中的作用是有必要的.
相关概念视频
01:30Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
160
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
160
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
7.4K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.4K
02:07Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
01:30Inflammatory Bowel Disease II: Crohn's Disease
240
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
240